Taysha Gene Therapies’ (TSHA) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $7.00 price target on the stock.

A number of other brokerages have also recently issued reports on TSHA. Cantor Fitzgerald restated an overweight rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Piper Sandler started coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an overweight rating and a $9.00 price objective on the stock. JMP Securities reaffirmed a market outperform rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Canaccord Genuity Group reissued a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Finally, Chardan Capital upped their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a buy rating in a research report on Thursday, March 21st. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $6.88.

Taysha Gene Therapies Trading Down 8.7 %

TSHA opened at $2.94 on Thursday. Taysha Gene Therapies has a fifty-two week low of $0.50 and a fifty-two week high of $3.89. The company has a market cap of $549.84 million, a price-to-earnings ratio of -4.39 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The firm has a 50 day simple moving average of $2.47 and a 200 day simple moving average of $2.11.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. On average, sell-side analysts anticipate that Taysha Gene Therapies will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 16.3% in the 4th quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company’s stock valued at $10,966,000 after purchasing an additional 867,703 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Taysha Gene Therapies during the fourth quarter worth about $148,000. Virtu Financial LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $46,000. Chicago Partners Investment Group LLC raised its position in Taysha Gene Therapies by 21.4% in the 4th quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock valued at $239,000 after buying an additional 23,740 shares during the last quarter. Finally, Exome Asset Management LLC bought a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $1,227,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.